|
Title
|
|
|
|
The value of []fluoro-2-deoxy-d-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Combined modality treatment (CMT) for patients with stage IIIA-N2 non-small cell lung cancer (NSCLC) is at present studied extensively. To select patients with truly stage IIIA-N2 disease, however, proves to be difficult with current diagnostic tests. Distant metastases may become clinically overt during induction chemotherapy (IC) or shortly after, revealing the inaccuracies of current staging algorithms. A prospective study with [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG PET) in IIIA-N2 NSCLC patients was performed to assess its value in the selection of this patient group. Fifty-seven patients received a whole body FDG PET scan as part of an ongoing response monitoring trial. Results were compared with conventional staging. In 32/57 (56%) PET suggested upstaging, which was confirmed in 17/57 (30%) with a median follow-up of 16 (range 249) months. These results show that using the conventional staging algorithm a substantial group of patients was understaged. FDG PET improves the selection of patients suitable for CMT. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Lung cancer: journal of the International Association for the Study of Lung Cancer / International Association for the Study of Lung Cancer [Aurora, Colo.] - Amsterdam
|
|
|
Publication
|
|
|
|
Amsterdam
:
2003
|
|
|
ISSN
|
|
|
|
0169-5002
|
|
|
DOI
|
|
|
|
10.1016/S0169-5002(02)00446-4
|
|
|
Volume/pages
|
|
|
|
39
:2
(2003)
, p. 151-157
|
|
|
ISI
|
|
|
|
000181220800007
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|